No trading implications from this filing - it's a routine disclosure completion. Monitor the company's next quarterly filing for any material operational or financial updates.
Price Chart
Executive Summary
Rein Therapeutics filed an amended 10-K to include previously omitted Part III disclosures (Items 10-14) related to director and executive officer information, executive compensation, and principal accounting fees. The amendment was routine and did not involve any financial restatements or corrections.
Key Facts
- Amendment adds Part III disclosures (directors, executive compensation, related party transactions) that were omitted from the original 10-K filing
- No financial statements were amended or restated
- New certifications from CEO and CFO are included as required for amendments
- The filing confirms no material changes to corporate governance, executive compensation, or accounting practices
Financial Impact
No financial impact - this is a disclosure-only amendment
Risk Factors
- None identified from this amendment
- Standard biotech development risks remain for the company's pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-178787 |
| Document: 0001193125-26-178787-index.html | 0001193125-26-178787 |
| Document: 0001193125-26-178787.txt | 0001193125-26-178787 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.7042 (−20.80%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.7042 (−12.63%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.7042 (−21.30%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.7042 (−25.77%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.7042 (+30.96%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.7042 (+30.96%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.7042 (+31.63%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 28, 2026 26w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.7042 (−52.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers